HeimAMBI • NYSEAMERICAN
add
Ambipar Emergency Response
Við síðustu lokun
0,42 $
Árabil
0,20 $ - 0,55 $
Markaðsvirði
23,28 m. USD
Meðalmagn
5,28 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NYSEAMERICAN
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (BRL) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 817,26 m. | 10,36% |
Rekstrarkostnaður | -21,56 m. | -262,28% |
Nettótekjur | -99,58 m. | -226,98% |
Hagnaðarhlutfall | -12,18 | -196,35% |
Hagnaður á hvern hlut | — | — |
EBITDA | 138,17 m. | -17,75% |
Virkt skatthlutfall | -34,76% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (BRL) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 358,43 m. | -15,32% |
Heildareignir | 5,80 ma. | 34,60% |
Heildarskuldir | 3,98 ma. | 34,93% |
Eigið fé alls | 1,82 ma. | — |
Útistandandi hlutabréf | 55,43 m. | — |
Eiginfjárgengi | 0,02 | — |
Arðsemi eigna | 3,94% | — |
Ávöxtun eigin fjár | 4,63% | — |
Peningaflæði
Breyting á handbæru fé
| (BRL) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -99,58 m. | -226,98% |
Handbært fé frá rekstri | 110,44 m. | 35,69% |
Reiðufé frá fjárfestingum | 77,48 m. | 184,48% |
Reiðufé frá fjármögnun | -381,16 m. | -157,73% |
Breyting á handbæru fé | -82,47 m. | 5,91% |
Frjálst peningaflæði | -260,36 m. | -2.494,33% |
Um
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013, and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange. Wikipedia
Stofnsett
1. jan. 2000
Höfuðstöðvar
Vefsvæði
Starfsfólk
53
